|
|
|
|
Pharmaceutical Manufacturing and Packing Sourcer |
| |
|
Pharmaceutical Manufacturing and Packing Sourcer (PMPS) is a specialist journal designed to provide worldwide coverage of a range of topics relating to the pharmaceutical manufacturing and packaging sector.
Published quarterly, the journal functions as a platform of communication and information-sharing for executive and strategic decision-makers within the industry, identifying new trends and marketing opportunities as well as highlighting the latest innovations in this dynamic environment. PMPS is specifically designed to interest those in the pharmaceutical, biotech, nutritional and medical device industries who are actively seeking to source services for improved efficiency in what is an increasingly competitive market.
We're also on Twitter! Follow us @PMPSmag
Read
our publications on the go in the Samedan app for iPhone and iPad. You
can download issues for offline reading and our archives go as far back
as 2008! Download for free on the App Store. 
|
|
|
|
|
|
 |
Industry Events |
 |
Clinical Outsourcing and Partnering World Europe
10-11 March 2015, Business Design Centre, London
The 8th
annual Clinical Outsourcing and Partnering World Europe examines strategies to
drive forward clinical trials for the better in order to deliver the best
outcome for patients.
More info >> |
|
 |
News and Press Releases |
 |
Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets
Cambridge,
UK, 25 February 2015 – Mundipharma International Limited’s network of
independent associated companies are launching Remsima® (infliximab)
this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg
following expiry of the relevant patents and Supplementary Protection
Certificates, having secured distribution rights from Celltrion
Healthcare Hungary Kft for Remsima in these markets.
More info >> |
|
 |
White Papers |
 |
|
Pharmacovigilance and Risk Management Information in Centralised Applications in the EU
United BioSource Corporation (UBC)
Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >> |
|
|
